🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

505 results for “Oral” Clear

  1. DEXTROMETHORPHANE ELERTE 1,5 mg/ml, sirop, AZD3470, AZD3470, Midazolam-ratiopharm® 2 mg/ml orale Lösung

    AstraZeneca AB

    Advanced/metastatic solid tumors that are MTAP deficient.

    phase 1 small molecule active

    1 trial

  2. DOSE-FINDING CLINICAL TRIAL TO EVALUATE OF INTESTINAL LACTASE ACTIVITY VIA ORAL GAXILOSE ADMINISTRATION IN HEALTHY ADULT VOLUNTEERS

    Lacuna Pharma Pty Ltd

    Hypolactasia

    phase 1 other active

    1 trial

  3. Dexlansoprazole Delayed Release Orally Disintegrating Tablets

    Takeda

    Bioavailability

    phase 1 small molecule completed

    1 trial

  4. Empagliflozin 10 MG Oral Tablet [Jardiance]

    BRIGHT MINDS BIOSCIENCES INC.

    Diabetes Mellitus

    phase 1 small molecule completed

    1 trial

  5. Epidiolex 100 mg/mL Oral Solution

    Jazz Pharmaceuticals Ireland Limited

    Electrical Status Epilepticus of Slow-Wave Sleep

    phase 1 small molecule completed

    1 trial

  6. FTX-6058/placebo oral capsule(s)

    Fulcrum Therapeutics

    Healthy Adult Subjects

    phase 1 small molecule completed

    1 trial

  7. GC4419

    Galera Therapeutics

    Squamous Cell Carcinoma of the Oral Cavity

    phase 1 small molecule completed

    1 trial

  8. GC4711 Oral Capsule G-101

    Galera Therapeutics

    Healthy Volunteers

    phase 1 small molecule completed

    1 trial

  9. GLPG1205 single ascending doses, oral suspension

    Lakefront Biotherapeutics NV

    Healthy

    phase 1 small molecule completed

    1 trial

  10. GLPG1972 600 mg oral solution fasted

    Lakefront Biotherapeutics NV

    Osteoarthritis

    phase 1 small molecule completed

    1 trial

  11. GLPG3667 oral suspension

    Lakefront Biotherapeutics NV

    Healthy

    phase 1 small molecule completed

    1 trial

  12. GLPG3970 oral solution

    Lakefront Biotherapeutics NV

    Healthy

    phase 1 small molecule completed

    2 trials

  13. GLPG4059 oral suspension

    Lakefront Biotherapeutics NV

    Healthy

    phase 1 small molecule terminated

    1 trial

  14. GLPG4399 oral suspension

    Lakefront Biotherapeutics NV

    Healthy

    phase 1 small molecule completed

    1 trial

  15. Losmapimod 15 mg oral tablet

    Fulcrum Therapeutics

    Healthy Adult Subjects

    phase 1 small molecule completed

    1 trial

  16. M1774 (oral ATR inhibitor) in Combination with PLX038 (Topo1 inhibitor) with dose expansion cohorts in patients with advanced solid tumors

    The George Institute

    Patients with pretreated, metastatic or locally advanced cancer for the dose escalation part and dose expansion cohorts in patients with advanced triple-negative breast cancers and advanced cancers with ATM mutation.

    phase 1 other active

    1 trial

  17. Mass Balance and Absolute Oral Bioavailability of [14C]VH4524184

    ViiV Healthcare Pty Ltd

    human immunodeficiency virus (HIV)

    phase 1 other active

    1 trial

  18. Mirtazapine 15 mg (Orally Disintegrating) Tablets

    Teva Pharma GmbH

    Healthy

    phase 1 small molecule completed

    2 trials

  19. Multiple Dose Study of RO7795068 and its effect on Gastric Emptying, and on PK of Oral Contraceptives

    Hoffmann-La Roche

    Healthy Overweight or Obese

    phase 1 other active

    1 trial

  20. Neoadjuvant chemotherapy

    Hospital Authority, Hong Kong

    Squamous Cell Carcinoma of Oral Cavity

    phase 1 small molecule completed

    1 trial

  21. Nifedipine 60 MG Extended Release Oral Tablet

    BRIGHT MINDS BIOSCIENCES INC.

    Healthy Volunteers

    phase 1 small molecule completed

    1 trial

  22. Open label, Phase I study to assess and compare the pharmacokinetic parameters after multiple oral administration of stiripentol 1000 mg in renal impaired patients and matching controls with normal renal function

    Biocodex

    Patients with renal impairement

    phase 1 other active

    1 trial

  23. Open label, single-center, cross-over randomized, relative bioavailability study comparing a new pitolisant hydrochloride tablet formulation versus the marketed pitolisant (Wakix®) tablet formulation after single oral administrations in healthy subjects.

    Bioprojet Pharma

    narcolepsy with cataplexy, Narcolepsy

    phase 1 other active

    1 trial

  24. Open label, single-center, cross-over randomized, relative bioavailability study comparing a new pitolisant hydrochloride tablet formulation at 4 different strengths versus the marketed pitolisant (Wakix®) tablet formulation after single oral administrations in healthy subjects

    Bioprojet Pharma

    Narcolepsy, Narcolepsy with cataplexy

    phase 1 other active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources